Navigation Links
Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
Date:2/15/2008

hese cancers in addition to prostate cancer."

In the combination Phase 1 dose-escalating study, 33 patients were treated with one of four doses (60, 80, 100 or 120 mg/m squared) of picoplatin, as well as either 60 mg/m squared or 75 mg/m squared (full-dose) docetaxel plus 5 mg prednisone twice daily. Nine patients received 120 mg/m squared picoplatin and 75 mg/m squared docetaxel every 21 days plus 5 mg prednisone twice daily. This dose, which is also the dose currently under study in the Phase 2 trial, was well tolerated.

Hematological toxicity, including neutropenia, anemia and thrombocytopenia, was dose-dependent and reversible. Neutropenia was the dose-limiting toxicity (DLT). Mild neuropathy (grade 1) was observed in 3 of 33 patients (9 percent) and was unrelated to cumulative picoplatin dose. Neuropathy was infrequent, and no neuropathy of grade 2 or greater was observed. PSA response rate was 65 percent (20 of 31 evaluable patients). Survival data are not yet available. Patient withdrawal from study treatment occurred from death in four patients, progressive disease in eight patients, and withdrawal of consent in one patient. Patients in the Phase 1 trial received a median number of 7 cycles, and 13 of 33 patients completed the maximum of 10 cycles of treatment according to the study protocol.

Based on safety and efficacy data from the Phase 1 study, the recommended Phase 2 regimen of intravenous picoplatin (120 mg/m squared) and docetaxel (75 mg/m squared) every 21 days with prednisone (5 mg) orally twice daily is being evaluated in a Phase 2 study in chemotherapy naive mHRPC patients. PSA response is the primary endpoint; secondary endpoints include radiological response using RECIST criteria, time to progression and survival (1-year, progression-free and overall). The Phase 2 trial completed enrollment in December 2007. The Company expects to present the results of this study in scientific forums later this year.

About Picoplati
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
2. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
3. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
4. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
5. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
6. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
7. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
8. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
9. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
10. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
11. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... and DUBLIN , Jan. 23, 2015 ... with KRS Global Biotechnology, Inc. for the compounding, packaging and ... for shipment in the United States . ... Outsourcing Facility capable of compounding naltrexone tablets in various strengths ...
(Date:1/23/2015)... Jan. 23, 2015  iMD Companies, Inc. (ICBU) has repositioned itself ... share and grab a foothold in the hydroponic, hemp and ... and a presence in the sector, and recently partnering with ... of hemp and medical marijuana, iMD is committing to bring ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... Directors has approved a share repurchase program. The open-ended ... million of Mallinckrodt plc ordinary shares. ... remain top priorities as we continue to pursue a ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... N.C. , July 23 Sales executives agree that ... process. Yet only 6 percent of district sales managers currently understand ... , , , ... knowledge of health outcomes, evidence based medicine and reimbursement," states an ...
... July 23 The North Shore-LIJ Health System Department of ... oropharynx (back of the mouth) to participate in a Phase I clinical ... Subjects must be ... must be unassociated with the human papilloma virus (HPV-negative), or, if it ...
Cached Medicine Technology:Health Outcomes Data Essential to Biopharmaceutical Sales Process 2Health Outcomes Data Essential to Biopharmaceutical Sales Process 3Study Seeks Volunteers to Measure Safety of Treatment 'Boost' for Patients with Oropharyngeal Cancer 2
(Date:1/22/2015)... 23, 2015 LunaDress, with its top dressmaking ... industry. Now, the business is showing its latest designs of ... , According to the company’s CEO, all the fresh new ... with big discounts, up to 80% off. All the clothes ...
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort located in ... number one best large hotel for families in the United ... annual Travelers’ Choice Awards. , TripAdvisor represents the world’s ... to millions of unbiased and honest traveler reviews. The best ...
(Date:1/22/2015)... 2015 Padre Murphy's and Owner Tom Boyle ... Pro Player Health Alliance (PPHA). The PPHA's passion for ... everyone, including NFL greats, treated for obstructive sleep apnea (OSA) ... supporting the cause in the valley. The most recent plans ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The Incredible Bulk ... Ben Pakulski to increase lean muscle by up to 30lbs ... caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative ... it is a step-by-step, scientific diet formula that allows the ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) ... to “Live Fearless.” , The “Faces of Fearless” ... about how they or someone they know has faced a ... the moment. By telling these types of stories through livefearlessmn.com, ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2
... Sept. 17 Adlyfe, a private company,developing novel ... announced today that it has appointed Roxanne Duan, ... be responsible for overseeing,the Adlyfe,s Research efforts and ... Duan comes to Adlyfe with nearly two decades ...
... Symmetry Medical Inc.,(NYSE: SMA ), an ... industry and other medical markets, announced today the ... http://www.symmetrymedical.com, which contains improved,user- friendly features. ... provides easy to,find product information and a streamlined ...
... affect asthma type, study concludes, , , MONDAY, Sept. ... affect the type of asthma you develop, new ... youngsters in affluent, developed countries had more allergy-triggered ... developed countries. , "The link between atopic ...
... available, researchers must recruit hundreds or thousands of patients ... patients is often difficult. Many potential candidates are unaware ... logistical hurdles. As a result, patients miss out on ... therapies take longer to reach the public., In a ...
... Sept. 17 CryoCor, Inc. (Nasdaq:,CRYO), a medical device ... that Edward F. Brennan, President and Chief,Executive Officer, and ... at the Maxim Group First Annual Growth Conference in,New ... a.m. ET at The Grand,Hyatt Hotel. A live ...
... largest public health challenges, including AIDS, should be part of Presidential ... ... plans, WASHINGTON, Sept. 17 More than 100,organizations ... to ending the AIDS epidemic in America. They have requested that,every ...
Cached Medicine News:Health News:Adlyfe Appoints Roxanne Duan as Vice President of Research 2Health News:Adlyfe Appoints Roxanne Duan as Vice President of Research 3Health News:Symmetry Medical Launches New Global Web site 2Health News:Symmetry Medical Launches New Global Web site 3Health News:Allergy-Induced Asthma More Common in Affluent Countries 2Health News:Allergy-Induced Asthma More Common in Affluent Countries 3Health News:IMPACT initiative looks to improve patient participation in clinical trials 2Health News:CryoCor to Present at Maxim Group First Annual Growth Conference in New York 2Health News:More Than 100 Organizations Call for a National AIDS Strategy to End the Epidemic in the United States 2Health News:More Than 100 Organizations Call for a National AIDS Strategy to End the Epidemic in the United States 3
Two point fixation, tips separated by 13 mm. Each tip has 0.12 mm, 1 x 2 teeth. Wide serrated handle with thumb catch lock and dull finish....
... A simple, effective method for determining color ... reliable data which can be applied to ... The set consists of four trays containing ... caps that have incremental hue variation on ...
... Farnsworth 100 Hue Test including MS-Excel scoring template ... Farnsworth 100 Hue Test comes boxed in clear ... the potential for test disruption by holding ... test from Richmond Products includes 93 color discs, ...
... modification of the Farnsworth-Munsell 100 Hue Test. It ... the in-depth study of a color vision defect. ... ease or difficulty in distinguishing color differences in ... 15 color reference caps with Munsell notations, plus ...
Medicine Products: